Europe Just Pulled the Plug on an Amgen Drug. The Reason Is Unprecedented.
Europe's drug regulator just recommended revoking Amgen's Tavneos over "incorrect and misleading" clinical trial data, one of the rarest regulatory actions in EU history. The move raises uncomfortable questions about how many approved drugs could survive a second look at their pivotal studies.
Imagine buying a house, moving in, and then finding out the inspection report was fabricated. The foundation might be fine. Or it might not. But you'd never really know, because the person who checked it lied.
That's essentially what just happened to Amgen's Tavneos (avacopan), a drug for rare autoimmune vasculitis, in Europe. And the fallout could ripple across the entire industry.
The Rarest of Rare Regulatory Actions
Europe's top drug advisory body, the CHMP (the committee that evaluates medicines for the EU), just recommended revoking Tavneos' marketing authorization. Not suspending it. Not slapping a warning on the label. Revoking it entirely, meaning the drug should no longer be sold anywhere in the EU.
The reason? The clinical trial data that got the drug approved in the first place were, in the committee's words, "incorrect and misleading."
To put this in perspective: a 2018 review found only 18 total cases of withdrawals, revocations, or suspensions of EU-approved medicines over the period studied. Of those, just two were outright revocations. And almost all of them were triggered by safety problems discovered after approval, not by someone going back and finding the original homework was copied.
Revocation over data integrity in a pivotal trial? That's nearly unheard of.
What Tavneos Was Supposed to Do
Tavneos is a complement C5a receptor inhibitor (think of it as a brake pedal for a specific part of the immune system that's attacking your own blood vessels). It was approved in the EU in 2022 for adults with two rare, severe autoimmune conditions: granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Both are forms of ANCA-associated vasculitis, where the immune system wages war on small blood vessels throughout the body.
These are serious diseases. Patients have limited treatment options. The approval was built on a single pivotal study called ADVOCATE, a Phase III trial enrolling 331 patients.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
And ADVOCATE is where everything fell apart.
The Trial That Couldn't Be Trusted
When regulators took a hard look at the ADVOCATE trial, they found it had been conducted in breach of Good Clinical Practice (GCP) principles, the set of ethical and scientific quality standards that every clinical trial is supposed to follow. GCP is the bedrock of clinical research. Without it, you can't trust the numbers.
The CHMP concluded that the data submitted during Tavneos' original approval process were unreliable. The committee couldn't confirm whether the drug actually works as claimed, because the evidence supporting that claim was compromised. Amgen and its partners tried submitting post-marketing data and additional analyses to salvage the case, but the committee found those insufficient to re-establish proof of benefit.
The benefit-risk balance, which is the core calculation regulators use (does this drug help more than it hurts?), was now considered unfavorable. Not because new side effects emerged, but because the "benefit" side of the equation evaporated.
The FDA Saw It First
This didn't come out of nowhere. Back in January 2026, the U.S. FDA raised its own data integrity concerns about the ADVOCATE trial. The agency moved to withdraw Tavneos' U.S. approval after Amgen declined to voluntarily pull the drug. The FDA cited data manipulation concerns and potential liver injury risks.
The CHMP explicitly agreed with the FDA's assessment. That kind of transatlantic regulatory alignment is notable; these agencies often reach different conclusions on the same data. When both of them say "we can't trust this trial," the signal is about as clear as it gets.
What Happens Next (and Who Gets Hurt)
The CHMP's recommendation now goes to the European Commission, which makes the final, legally binding decision. If confirmed (and CHMP recommendations almost always are), Tavneos will be pulled from the EU market.
The immediate patient impact is already underway. CSL Vifor, which markets Tavneos in Europe, has reportedly stopped starting new patients on the drug in EMA-jurisdiction markets. The CHMP advised that current patients should consult their doctors and transition to alternative treatments.
For patients with GPA and MPA, this is genuinely painful. These are rare diseases; the patient population is small, and options are limited. Tavneos was the first complement C5a receptor inhibitor to reach the EU market for these conditions. Losing it means going back to older therapies that may be less targeted.
The Bigger Picture: A Warning Shot for the Industry
If the Tavneos story feels like an isolated scandal, the regulatory trend line says otherwise.
FDA Form 483 observations (the citations inspectors issue when they find problems) related to data integrity have risen steadily since 2020. In April 2024, the FDA issued new draft guidance specifically addressing data integrity in bioavailability and bioequivalence studies, explicitly reacting to "recent observed data integrity concerns." The EMA published detailed guidelines on computerized systems in clinical trials in 2023, with requirements for audit trails, electronic signatures, and data lifecycle controls.
The finalization of ICH E6(R3) in January 2025 introduced a "Quality by Design" framework that makes sponsors identify and manage critical data integrity risks from the start of a trial, not as an afterthought. Both the FDA and EMA adopted it within months.
In December 2024, the FDA hit Applied Therapeutics with a warning letter over significant data integrity concerns in clinical trial data, including missing source documents. Regulators are clearly no longer treating sloppy record-keeping as a minor infraction.
The message to every biotech company running clinical trials is straightforward: your pivotal data will be scrutinized long after approval, and if regulators find it was built on sand, they will tear down the house.
The Uncomfortable Question
Tavneos was approved by the FDA in 2021 and the EU in 2022. The ADVOCATE trial's problems weren't caught until years later. That raises an uncomfortable question: how many other approved drugs are sitting on data that wouldn't survive a second look?
No one knows the answer. But regulators on both sides of the Atlantic are making it very clear they intend to find out.
Clinical & Regulatory
4 min read
The FDA Fired Thousands of People. Now It's Hiring 2,200 Back.
The FDA slashed 3,000 workers last year. Now it's scrambling to hire 2,200 back, but the math still doesn't add up. Here's what it means for drug approvals, biotech timelines, and whether the regulatory engine can survive the whiplash.
